Synektik operations and oncology focus, shares watched by Polish investors
Published on 06/26/2026 at 17:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 17:08.
Synektik S.A. (PLSYNEK00016) remains a niche healthcare player on the Warsaw exchange, active in advanced imaging systems and radiopharmaceuticals for oncology diagnostics. The company positions itself as a key supplier of PET/CT solutions and radioisotopes in Poland, according to recent corporate information.
Business centered on imaging and radiopharma
Synektik reports a business model that combines distribution and servicing of diagnostic imaging equipment such as PET/CT and MRI scanners with in-house production of radiopharmaceuticals used in oncology and cardiology. The group also develops IT solutions for imaging workflow and clinical decision support in nuclear medicine.
The company operates radiopharmaceutical production facilities designed to supply hospitals and diagnostic centers with short-lived isotopes, including products based on fluorine-18 for PET imaging. Synektik highlights long-term supply contracts with medical providers as a way to secure recurring revenue streams from consumables alongside equipment and service sales.
Position in the Polish healthcare market
Synektik targets the growing demand for oncological diagnostics in Central and Eastern Europe, with a core focus on the Polish hospital and outpatient clinic segment. The company competes with global imaging vendors such as Siemens Healthineers and GE HealthCare on equipment, while differentiating through localized service and radiopharmaceutical offerings.
In its communication, Synektik underlines the importance of demographic trends and increasing cancer incidence in Poland as drivers for PET/CT and SPECT diagnostics. The Warsaw listing offers regional investors exposure to medical technology and nuclear medicine themes, similar in part to larger European healthcare equipment groups on indices such as the Stoxx Europe 600 Health Care.
What the company sells today
Synektik currently markets radiopharmaceuticals and comprehensive PET/CT system solutions for oncology centers, combining isotope supply, imaging hardware and IT tools for diagnostic workflows. The business aims to provide end-to-end support from installation and servicing of scanners to regular deliveries of radioisotopes to clinical partners.
Where the stock trades today
Synektik S.A. shares trade on the Warsaw Stock Exchange in Polish zloty, offering investors exposure to the regional medical technology and radiopharmaceutical sector.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
